Conditions: Gastrointestinal Cancer Metastatic Renal Cell Cancer Metastatic Non Small Cell Lung Cancer Metastatic
Keywords: Metastatic Gastrointestinal Metastatic Kidney Metastatic Lung
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 18
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine whether the combination of a 5-Fluorouracil (5-FU) and interferon, which is able to stimulate the immune system to kill cancer cells, will help to increase tumor shrinkage in previously-treated metastatic gastrointestinal, kidney, or lung Cancer.

Detailed description:
Interferon with continuous infusion 5-Fluorouracil (5-FU) regimens have shown response rates ranging from 0-43% in various cancers. Monthly bolus 5-FU + interferon-alfa-2b has not undergone formal phase II testing. In a small pilot study, a 5 consecutive day schedule of 5-FU and interferon-alfa-2b resulted in the limiting toxicities of diarrhea and mucositis. A more limited schedule was recommended. Therefore, it is reasonable to examine such a schedule. In the current study, 5-FU will be followed by interferon-alfa-2b daily for 3 days to attempt to benefit from both the biochemical and immunologic mechanisms described above.

Arms:
arm 1: 5-Fluorouracil

Interferon-alfa-2b

Interventions: intervention 1: 5-Fluorouracil and Interferon
Intervention descriptions: intervention 1: 5-Fluorouracil Interferon-alfa-2b

Protocol document: